Get the Stockscreener App
29.13
2.08%
-0.62
Collegium Pharmaceutical Inc stock is traded at $29.13, with a volume of 290.26K.
It is down -2.08% in the last 24 hours and down -12.23% over the past month.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
See More
Previous Close:
$29.75
Open:
$30.02
24h Volume:
290.26K
Relative Volume:
0.75
Market Cap:
$939.45M
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
24.48
EPS:
1.19
Net Cash Flow:
$274.29M
1W Performance:
-1.79%
1M Performance:
-12.23%
6M Performance:
-18.22%
1Y Performance:
-8.28%
1-Day Range:
$28.77
$30.21
1-Week Range:
$28.77
$30.39
52-Week Range:
$28.39
$42.29
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
29.13 | 939.45M | 566.77M | 48.16M | 274.29M | 1.19 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Needham | Hold → Buy |
| Jul-30-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-07-24 | Upgrade | Jefferies | Hold → Buy |
| May-10-24 | Downgrade | Needham | Buy → Hold |
| May-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-25-23 | Reiterated | Needham | Buy |
| May-02-23 | Resumed | Jefferies | Buy |
| Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Jul-14-20 | Initiated | BWS Financial | Sell |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Feb-19-20 | Resumed | Jefferies | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-03-19 | Resumed | H.C. Wainwright | Buy |
| Apr-12-19 | Resumed | Janney | Buy |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Jan-16-19 | Reiterated | Needham | Buy |
| Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-18 | Reiterated | Needham | Buy |
| Dec-05-17 | Reiterated | Needham | Buy |
| Sep-11-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Reiterated | Needham | Buy |
| Sep-13-16 | Initiated | Gabelli & Co | Buy |
| Jun-01-15 | Initiated | Jefferies | Buy |
| Jun-01-15 | Initiated | Needham | Buy |
| Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Empowered Funds LLC Sells 104,871 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday - MarketBeat
Collegium Pharmaceutical (COLL) Expected to Announce Quarterly Earnings on Thursday - Defense World
Collegium Pharmaceutical (NASDAQ:COLL) versus Atea Pharmaceuticals (NASDAQ:AVIR) Critical Survey - Defense World
When (COLL) Moves Investors should Listen - Stock Traders Daily
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
Collegium Pharmaceutical, Inc. to Report Q4 and Full-Year 2024 Financial Results on February 27, 2025 - Nasdaq
Earnings Alert: Collegium Sets Critical Q4 & FY2024 Financial Results DateMark Your Calendar - StockTitan
Collegium Pharmaceutical expands board, appoints new director - MSN
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average Target Price from Analysts - Defense World
Robeco Institutional Asset Management B.V. Has $293,000 Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Lowered to $36.00 at Piper Sandler - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Position Raised by Caprock Group LLC - Defense World
Piper Sandler Has Lowered Expectations for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price - Defense World
Collegium Pharmaceutical, Inc. Appoints Nancy S. Lurker to Its Board of Directors -February 05, 2025 at 08:00 am EST - Marketscreener.com
Collegium Pharmaceutical expands board, appoints new director By Investing.com - Investing.com Australia
Collegium Pharmaceutical expands board with new director - MSN
Collegium Appoints Nancy S. Lurker to its Board of Directors - citybiz
Collegium Pharmaceutical expands board with new director By Investing.com - Investing.com South Africa
Collegium Pharmaceutical Expands Board with Nancy Lurker - TipRanks
Collegium Pharmaceutical Insiders Sell US$2.3m Of Stock, Possibly Signalling Caution - Simply Wall St
SG Americas Securities LLC Sells 4,586 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical, Inc. announces an Equity Buyback for $100 million worth of its shares. - Marketscreener.com
Pacer Advisors Inc. Trims Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Nisa Investment Advisors LLC Has $71,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check - FiercePharma
Collegium Pharmaceutical Appoints Chief Financial Officer and New Member to its Board of Directors - ACCESS Newswire
Collegium Pharmaceutical, Inc. to Host Earnings Call - ACCESS Newswire
Assenagon Asset Management S.A. Trims Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Assenagon Asset Management S.A. Has $4.31 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Ritholtz Wealth Management Has $968,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Needham Upgrades Collegium Pharmaceutical (COLL) - MSN
Burney Co. Sells 38,157 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $43.80 - Defense World
Collegium pharmaceutical EVP Shirley Kuhlmann sells $908,627 in stock By Investing.com - Investing.com Australia
Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells 27,500 Shares of Stock - MarketBeat
Despite the downward trend in earnings at Collegium Pharmaceutical (NASDAQ:COLL) the stock swells 18%, bringing three-year gains to 82% - Simply Wall St
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
JPMorgan Chase & Co. Has $10.71 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
JPMorgan Chase & Co. Grows Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC Wainwright - Defense World
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Collegium Pharmaceutical Inc Stock (COLL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kuhlmann Shirley R. | EVP and General Counsel |
Jan 10 '25 |
Sale |
33.04 |
27,500 |
908,628 |
119,184 |
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):